AvenCell Begins Trial for 'Off-the-Shelf' CAR-T Cancer Therapy

WATERTOWN, Mass. – April 02, 2026 – AvenCell Therapeutics announced today it has dosed the first patient in a landmark clinical trial for AVC-203, a next-generation cell therapy designed for patients with relapsed or refractory B-cell malignancies. The move signals a critical step forward in the quest for an “off-the-shelf” cancer treatment that could overcome the significant cost and logistical hurdles of current personalized therapies.

The Phase I QUADvance study will evaluate AVC-203, the world's first CRISPR-engineered allogeneic CAR-T therapy that simultaneously targets two cancer antigens and features a controllable “switch.” For patients with aggressive blood cancers like diffuse large B-cell lymphoma (DLBCL) who have exhausted other options, this new approach offers a potential lifeline.

Overcoming the Hurdles of Personalized Medicine

Chimeric antigen receptor (CAR) T-cell therapy has been a revolutionary force in oncology, offering durable remissions for patients with certain blood cancers. Approved autologous therapies like Yescarta and Kymriah work by harvesting a patient’s own T-cells, genetically engineering them to recognize and attack cancer, and infusing them back into the body.

However, this highly personalized process is fraught with challenges. The manufacturing timeline can take several weeks, a perilous waiting period for patients with rapidly advancing disease. The logistical complexity and bespoke nature of the treatment also contribute to a staggering price tag, often running into hundreds of thousands of dollars per patient, limiting global access. Furthermore, not all patients are eligible due to poor T-cell health, and a significant portion eventually relapses, often because their cancer learns to hide from the therapy by shedding the single antigen the CAR-T cells are trained to find.

Allogeneic, or “off-the-shelf,” therapies like AVC-203 aim to solve these problems. By using T-cells from healthy, pre-screened donors, AvenCell can create large batches of a standardized, ready-to-use product. This could dramatically reduce costs, eliminate manufacturing delays, and make CAR-T therapy immediately available to a much broader patient population.

“Patients with relapsed/refractory B-cell malignancies who have exhausted currently available treatment options, including approved autologous CAR-T therapies, have limited alternatives and a poor prognosis,” said Professor Martin Wermke, Head of the Early Clinical Trial Unit at the National Cancer Center Dresden, Germany. “AvenCell's allogeneic approach, combined with its innovative dual-targeting and switchable technology, represents a promising new therapeutic strategy for these patients.”

A Four-Pronged Attack on Cancer

AVC-203 is not just another allogeneic therapy; it integrates four distinct innovations to create what the company hopes is a more robust and controllable treatment.

First is its dual-antigen targeting. The therapy is engineered to recognize and attack cancer cells expressing either CD19 or CD20, two well-known markers on B-cell malignancies. By targeting both simultaneously, AVC-203 is designed to prevent a common resistance mechanism known as antigen escape, where cancer cells stop expressing the targeted marker to evade destruction.

Second, the therapy relies on advanced CRISPR/Cas9 gene editing to make the donor cells safe for a patient. AvenCell uses a proprietary editing sequence to remove the T-cell’s native receptors, preventing them from attacking the patient’s healthy tissues (Graft-versus-Host Disease), while also cloaking the cells from the patient’s own immune system to prevent rejection. This immune evasion is critical for ensuring the therapy can persist long enough to be effective.

Third, AvenCell has developed a proprietary manufacturing process that leverages the consistent fitness of T-cells from healthy donors, enabling off-the-shelf availability and scalable production. This is the key to the company’s goal of massively scaling supply and dramatically reducing costs.

Finally, AVC-203 incorporates a switchable targeting system. This novel feature, using the company's RevCAR technology, not only allows for future expansion to target other cancer antigens but also provides a mechanism to potentially control the therapy’s activity after infusion, a significant safety advantage.

Strategic Backing and Global Ambitions

The development of such a complex therapy requires immense resources and expertise, and AvenCell is built on a powerful foundation. The company was founded in 2021 by a trio of industry heavyweights: Blackstone Life Sciences, a major investment firm providing financial muscle; Cellex Cell Professionals, a leader in cell sourcing and manufacturing; and Intellia Therapeutics, a pioneer in CRISPR gene-editing technology. This combination of capital, manufacturing know-how, and cutting-edge science gives the company a significant strategic advantage.

“Dosing the first patient with AVC-203 is a significant milestone for AvenCell and for the field of allogeneic cell therapy,” said Andrew Schiermeier, AvenCell's President & CEO. He emphasized the company’s focus on making CAR-T therapy universally accessible through scalable supply and reduced costs.

Underscoring the global interest in the platform, the AVC-203 program is supported by a grant of up to $40 million from the Japan Agency for Medical Research and Development (AMED). This non-dilutive funding not only validates the scientific approach but also paves the way for clinical development in Japan and the wider Asia-Pacific region. The QUADvance study has already received regulatory clearance from both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), enabling trial sites to open across the US and Europe.

The Road Ahead in a Competitive Field

The QUADvance study is a Phase I/II trial designed to first establish the safety and optimal dose of AVC-203 before evaluating its efficacy. In this early stage, investigators will be closely monitoring for potential side effects, including Graft-versus-Host Disease and immune rejection, which are key challenges for any allogeneic therapy. The persistence of the CAR-T cells in the body will be a critical metric, as longer persistence is often correlated with more durable anti-cancer responses.

AvenCell enters a competitive field, with companies like Allogene Therapeutics and Cellectis also advancing their own allogeneic CAR-T candidates. However, AvenCell is betting that its unique combination of dual-targeting, CRISPR engineering for immune evasion, and switchable technology will provide a best-in-class profile. The initiation of this trial is the first major test of that hypothesis in humans, and the oncology community will be watching the initial safety and activity data with great interest. The results will provide the first clinical clues as to whether this multifaceted approach can truly deliver on the promise of a safer, more effective, and universally accessible cell therapy for cancer.